Travel to high altitude with pre-existing lung disease

被引:83
|
作者
Luks, A. M.
Swenson, E. R.
机构
[1] Univ Washington, Div Pulm & Crit Care Med, Puget Sound Vet Affairs Hlth Care Syst, Seattle, WA 98108 USA
[2] Seattle Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Seattle, WA USA
关键词
acute mountain sickness; high altitude; high-altitude cerebral oedema; high-altitude pulmonary oedema; hypoxia; lung disease;
D O I
10.1183/09031936.00052606
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The pathophysiology of high-altitude illnesses has been well studied in normal individuals, but little is known about the risks of high-altitude travel in patients with pre-existing lung disease. Although it would seem self-evident that any patient with lung disease might not do well at high altitude, the type and severity of disease will determine the likelihood of difficulty in a high-altitude environment. The present review examines whether these individuals are at risk of developing one of the main forms of acute or chronic high-altitude illness and whether the underlying lung disease itself will get worse at high elevations. Several groups of pulmonary disorders are considered, including obstructive, restrictive, vascular, control of ventilation, pleural and neuromuscular diseases. Attempts will be made to classify the risks faced by each of these groups at high altitude and to provide recommendations regarding evaluation prior to high-altitude travel, advice for or against taking such excursions, and effective prophylactic measures.
引用
收藏
页码:770 / 792
页数:23
相关论文
共 50 条
  • [21] Pre-Existing Liver Disease and Toxicity of Antifungals
    Spernovasilis, Nikolaos
    Kofteridis, Diamantis P.
    JOURNAL OF FUNGI, 2018, 4 (04)
  • [22] Pre-Existing Coronary Artery Disease in Lung Transplantat Recipients: Does It Impact Outcomes?
    Khandhar, S.
    Tefera, L.
    Volz, E.
    Selzer, F.
    Kormos, R.
    Bermudez, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [23] Clinical Significance of Pre-existing Interstitial Lung Disease in Patients With COVID-19
    Watanabe, N.
    Tanino, Y.
    Nikaido, T.
    Yuki, S.
    Togawa, R.
    Kawamata, T.
    Wang, X.
    Fukuhara, N.
    Kazama, K.
    Sato, R.
    Yamada, R.
    Tomita, H.
    Suzuki, Y.
    Saito, J.
    Kanazawa, K.
    Shibata, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [24] Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
    Zhu, Lin
    Gao, Rong
    Li, Han
    Zheng, Yahui
    Yang, Junling
    IMMUNOTHERAPY, 2024, 16 (07) : 465 - 480
  • [25] THE IMPACT OF EMERGENCY SURGERY ON PATIENTS WITH PRE-EXISTING DISEASE
    SILVERSTEIN, ME
    MCGAVACK, TH
    WINFIELD, JM
    SURGICAL CLINICS OF NORTH AMERICA, 1955, 35 (02) : 319 - 333
  • [26] Milder disease with Omicron: is it the virus or the pre-existing immunity?
    Alex Sigal
    Nature Reviews Immunology, 2022, 22 : 69 - 71
  • [27] Lovastatin is not hepatotoxic to patients with pre-existing liver disease
    Avins, Andrew L.
    Manos, Michelle M.
    Levin, Theodore R.
    Ackerson, Lynn M.
    Zhao, Wei K.
    Murphy, Rosemary C.
    Watson, Douglas J.
    Hwang, Peggy May T.
    Replogle, Amy R.
    Levine, Jeffrey G.
    GASTROENTEROLOGY, 2006, 130 (04) : A595 - A595
  • [28] Survival of cancer patients with pre-existing heart disease
    O'Neill, Ciaran
    Donnelly, David W.
    Harbinson, Mark
    Kearney, Therese
    Fox, Colin R.
    Walls, Gerard
    Gavin, Anna
    BMC CANCER, 2022, 22 (01)
  • [29] Survival of cancer patients with pre-existing heart disease
    Ciaran O’Neill
    David W. Donnelly
    Mark Harbinson
    Therese Kearney
    Colin R. Fox
    Gerard Walls
    Anna Gavin
    BMC Cancer, 22